Incidence, prevalence, and management of opioid bowel dysfunction.
about
Effectiveness of the addition of Lidocaine to a hemostatic, bioresorbable putty in the treatment of iliac crest donor site painMu-opioid antagonists for opioid-induced bowel dysfunctionMu-opioid antagonists for opioid-induced bowel dysfunctionAvicenna's View on the Etiologies of Intestinal ObstructionOpioid-induced constipation: advances and clinical guidanceIntractable restless legs syndrome: role of prolonged-release oxycodone-naloxoneEvolving paradigms in the treatment of opioid-induced bowel dysfunctionDevelopments in managing severe chronic pain: role of oxycodone-naloxone extended releaseA critical appraisal of lubiprostone in the treatment of chronic constipation in the elderlyConsensus Recommendations on Initiating Prescription Therapies for Opioid-Induced ConstipationClinical potential of naloxegol in the management of opioid-induced bowel dysfunctionGut Microbiota: A Modulator of Brain Plasticity and Cognitive Function in AgeingChronic opioid induced constipation in patients with nonmalignant pain: challenges and opportunitiesOpioid-induced bowel dysfunction: prevalence, pathophysiology and burdenOpioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategiesDevelopment of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioidsEfficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations.Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart reviewRandomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation.Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Prevalence of opioid dispensings and concurrent gastrointestinal medications in QuebecPharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation.Opioid-induced constipation: pathophysiology, clinical consequences, and management.Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.Prevalence and clinical features of opioid-induced constipation in the general population: A French study of 15,000 individualsOxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceMethylnaltrexone: the evidence for its use in the management of opioid-induced constipation.Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipationReview article: palliative care in gynecologic oncology.Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.Novel opioid antagonists for opioid-induced bowel dysfunction.Prophylactic use of laxative for constipation in critically ill patientsOverview and treatment of opioid-induced constipation.Nonalcoholic fatty liver disease and aging: epidemiology to management.Prevalence of narcotic bowel syndrome in opioid abusers in iran.Advances in pharmacotherapy for opioid-induced constipation - a systematic review.Opioid-Induced Constipation.
P2860
Q21257164-BAA3C38A-C3E9-45B4-BB6D-6FB170B2FD38Q24243268-CA78CA39-7E49-4843-8689-9A25C70240F6Q24243361-46FBE4EB-D99A-4F81-9A32-39C33BC28D20Q26750621-8B79DAE6-0993-4701-B906-B74BBEB80A8AQ26765571-ECE894DB-40B4-4536-B6E9-328AA29A66BCQ26766416-A5CBF32E-16B0-4296-BDB2-26464307A92AQ26777692-8026FF5A-D3A7-4A50-BE23-D15C4A068AF3Q26801140-EEAAD40C-6C53-488C-A097-DEFDEE7FD574Q26824999-03247E51-0EFC-4A53-8D1B-3B0DD5EF0F81Q26830397-8B5320CE-A795-462A-8DE3-180339F61292Q26995944-8C6DB8AC-AFF2-4BD2-BD36-FB627360DA49Q28081092-00D420D8-979E-49C7-BC16-63BE969E0D55Q28083547-CBD3F6D1-91C9-4EA5-8521-97DF0F41EBF0Q28209970-6FD4DF95-CBCB-422C-83AD-C4CCAD5F79CAQ28294194-EA82D75C-02F2-4633-88AB-1EC723502806Q30989361-29797FA8-D9CA-4C8F-ABD9-8183E5C53F24Q31144449-3FE047CD-6FA4-4425-A7F3-61A6202DB3F0Q33296232-3D6370C7-5713-44DF-85E6-20A1F20492F7Q33461577-027B82DC-CB93-4143-AF8A-D6A7739DEEA6Q33461841-3FA228D6-723D-423D-824C-C842CD8D157EQ33462549-BADFE593-79E9-4496-9763-DF07E704B2E2Q33520508-B1685F82-1A43-4121-8101-4B40D069DFB3Q33562118-35ED6A6B-BC83-4095-89B0-EFCDCAB1A551Q33588365-4E529851-7A12-4D6D-8F1E-7976A65998DDQ33635040-BC96CD05-A571-49FF-8E64-31F73BAE9F59Q33709851-42EFB9B3-35EC-4C3D-A712-51C995A6A29CQ33731958-C2010CB3-5ABA-441B-ACB6-FF6BDD2B9F3AQ33938740-96476A51-8CB7-48B8-9E46-38A63BBB08F7Q33973870-64FD3B4E-6965-4845-9D54-A1DF2A0F7255Q34146166-EE2D26F9-F2C4-49E5-AB76-4FE1F330CD60Q34156710-7885CA8B-4935-4E61-83A7-41E3A43435B8Q34167814-E98CBC0F-6287-40DA-BB9A-2ED603198042Q34170592-924200C1-E26E-4C6A-A737-0CF6E601E4EFQ34191604-89865002-AF47-4DCD-9495-ADE64D187E5CQ34195940-6C74166A-6A62-44AC-9236-0756BC8FA59BQ34352001-D93E66E5-A434-48B1-8697-A446DD4614D0Q34366861-2F0E4B5D-31DD-4C89-8FEA-DC69D9F8A2D9Q34401446-DA5EEDF2-3190-4013-AA9D-F9B832641A56Q34455604-6AC4997A-B388-487D-8520-51E019AF5EEFQ34497803-346C8EFE-D347-4DA2-A19C-C789981B7E72
P2860
Incidence, prevalence, and management of opioid bowel dysfunction.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Incidence, prevalence, and management of opioid bowel dysfunction.
@ast
Incidence, prevalence, and management of opioid bowel dysfunction.
@en
Incidence, prevalence, and management of opioid bowel dysfunction.
@nl
type
label
Incidence, prevalence, and management of opioid bowel dysfunction.
@ast
Incidence, prevalence, and management of opioid bowel dysfunction.
@en
Incidence, prevalence, and management of opioid bowel dysfunction.
@nl
prefLabel
Incidence, prevalence, and management of opioid bowel dysfunction.
@ast
Incidence, prevalence, and management of opioid bowel dysfunction.
@en
Incidence, prevalence, and management of opioid bowel dysfunction.
@nl
P1476
Incidence, prevalence, and management of opioid bowel dysfunction.
@en
P2093
M Pappagallo
P304
P356
10.1016/S0002-9610(01)00782-6
P407
P433
P577
2001-11-01T00:00:00Z